Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children’s Oncology Group (COG) convened a rhabdomyosarcoma new agent task force in 2020 to systematicall...

Full description

Bibliographic Details
Main Authors: Holly L. Pacenta, Wendy Allen-Rhoades, David Langenau, Peter J. Houghton, Charles Keller, Christine M. Heske, Michael D. Deel, Corinne M. Linardic, Jack F. Shern, Elizabeth Stewart, Brian Turpin, Douglas J. Harrison, Javed Khan, Leo Mascarenhas, Stephen X. Skapek, William H. Meyer, Douglas S. Hawkins, Eleanor Y. Chen, James F. Amatruda, Pooja Hingorani, Theodore W. Laetsch
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
rhabdomyosarcoma
clinical trials
metastasis
relapse
new agents
Online Access:https://www.mdpi.com/2077-0383/10/7/1416

Internet

https://www.mdpi.com/2077-0383/10/7/1416

Similar Items